Quantcast
Last updated on April 23, 2014 at 17:36 EDT

The Trendlines Group Announces Co-development Agreement with Endo

November 13, 2012

TEL AVIV, Israel, November 13, 2012 /PRNewswire/ –

The Trendlines Group today announced it has entered into an R&D agreement aimed at
co-developing novel medical devices and technologies within the areas of pain and urology,
a strategic focus of U.S.-based Endo Health Solutions Inc. (Nasdaq: ENDP).

The work will be conducted by Trendlines Labs, the technology development arm of The
Trendlines Group. Trendlines Labs is co-located with the Misgav Venture Accelerator – The
Trendlines Group’s incubator focused exclusively on the development of medtech
innovations. Misgav was named “Best Incubator” by Israel’s Office of the Chief Scientist
of the Ministry of Industry, Trade and Labor [http://www.moit.gov.il ] in 2010. Trendlines
portfolio company Stimatix (http://www.stimatix-gi.com) was named Israel’s best
start-up in 2012.

D. Todd Dollinger, Chairman and CEO of Trendlines, stated, “Our work with Endo
furthers our market reach and is instrumental to our achieving our mission of creating and
developing businesses to improve the human condition.”

Dr. Sujat Sukthankar, Vice President, Device R&D, at Endo said, “The Trendlines-Endo
agreement is in line with our stated vision of sourcing innovation globally. This
partnership complements and bolsters our own internal innovation and product development
efforts in the areas of pain and urology. Through this partnership, we are excited to
participate in the vibrant medical technology community in Israel. ”

Endo Health Solutions Inc. (http://www.endo.com) is a U.S.-based diversified
healthcare company that is redefining healthcare value by finding solutions for the unmet
needs of patients along care pathways for pain management, pelvic health, urology,
endocrinology and oncology. Through its operating companies: Endo Pharmaceuticals,
Qualitest, AMS and HealthTronics, Endo is dedicated to improving care through a
combination of branded products, generics, devices, technology and services that creates
maximum value for patients, providers and payers alike.

About The Trendlines Group

The Trendlines Group (http://www.trendlines.com) creates and develops businesses
to improve the human condition. Principally through its two Israeli government-licensed
business accelerators, Trendlines invests in innovation-based businesses in the areas of
medtech and agritech, nurturing high-promise companies while mitigating seed-stage
investment risk. The Trendlines group owns the Misgav Venture Accelerator (
http://www.misgav-venture.com) which invests in and incubates promising medical device
companies and Trendlines Labs, which acts as Trendlines’ in-house invention factory,
inventing solutions to unmet market needs.

        Media relations:
        Efrat Sherer-Kaduri
        Ofir Shpigel Media and Public Relations
        +972-4-9535030

SOURCE The Trendlines Group


Source: PR Newswire